A New Chapter in PET/MR -- GE Healthcare's New SIGNA PET/MR

* World's first time-of-flight capable, integrated,
simultaneous PET/MR offers improved image quality

* Next-generation PET/MR enables oncology,
neurology, and cardiology imaging as never before

Waukesha, WI --- August 4, 2014 --- Today GE Healthcare announced that the first
integrated, simultaneous, time-of-flight (TOF) capable, whole body SIGNATM PET/MR
* is 510(k) pending at the FDA. Powered by simultaneous image acquisition from
GE's latest 3.0 Tesla magnetic resonance (MR) technology and innovative positron
emission tomography (PET) technology, the SIGNA PET/MR represents a new chapter
in helping clinicians achieve improved scan efficiency that may lead to more
effective treatment paths for clinicians to offer their patients, particularly
for oncology,
neurology, and cardiology.

MR is excellent for imaging soft tissue as well as
functional and morphological details. PET enables clinicians to visualize
cellular activity and metabolism. When these two powerful tools are combined,
clinicians may be able to see early cellular changes that can be accurately mapped
onto MR images. With this knowledge, clinicians may be able to shorten the time
between diagnosis and treatment, in addition to offering the convenience of
simultaneous PET and MR scans for patients. Research systems are installed at
Stanford University, University of California San Francisco, and University of

"We are excited about
SIGNA PET/MR because of its clinical and research potential," said
Dr. Andrei H. Iagaru, associate professor of
Radiology and Co-Chief of the Division of Nuclear Medicine and Molecular
Imaging at Stanford University Medical Center. "We have been using the system
for research and we are able to explore novel things in areas like neurology
and oncology, as well as in pediatrics in the future. Additionally, it's more
convenient for the patient due to simultaneous scanning. We can also initiate
innovative, complex research; simultaneity allows us to do functional neuro
imaging, cardiac imaging, and musculoskeletal imaging that we haven't been able
to do before. Time-of-flight offers improved image quality in PET/MR and with
the increased detector sensitivity, it may lead to future improvements in dose

The SIGNA PET/MR features GE's new, exclusive
MR-compatible silicon photomultiplier detector (SiPM) technology. This new digital
detector is characterized by its enhanced sensitivity; it is up to three times
more sensitive than conventional PET technology. It also features fast
coincidence timing resolution enabling TOF reconstruction. With TOF reconstruction,
the arrival times of each coincident pair of photons are more precisely detected,
and the time difference between them is used to localize the PET signal
accurately. TOF leads to improved PET image quality with higher structural
detail and improved signal-to-noise ratio. The SIGNA PET/MR is designed to be

upgradable from a Discovery MR750w 3.0T.

have received extremely positive feedback from our installations of the research
PET/MR systems," said Richard Hausmann, president and CEO of GE Healthcare MR. "Our
research partners are very excited by the performance of the system and the
potential of this new technology. We are proud to bring the first TOF-capable, simultaneous
PET/MR system, pending FDA clearance, to market."

is a trademark of the General Electric Company.

PET/MR is 510(k) pending at FDA. Not available for sale in the United States.
Not yet CE Marked. Not available for sale in all regions.

About GE

Healthcare provides transformational medical technologies and services to meet
the demand for increased access, enhanced quality and more affordable
healthcare around the world. GE (NYSE: GE) works on things that matter - great
people and technologies taking on tough challenges. From medical imaging,
software & IT, patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance improvement
solutions, GE Healthcare helps medical professionals deliver great healthcare
to their patients.

September 2011, GE Healthcare announced it would dedicate $1 billion of its
total R&D budget over the next five years to expand its advanced cancer
diagnostic and molecular imaging capabilities, as well as its world-class
technologies for the manufacture of biopharmaceuticals and for cancer research.
Additionally, between 2010 and 2020, GE Healthcare plans to invest over $500
million in research into neurological disorders. The investment crosses all
lines of GE Healthcare's global business and focuses on developing new
neurology diagnostic solutions, educating consumers, and expanding research
already in progress. In 2013, a $60 million investment with National Football
League to develop new MR technology for traumatic brain injury was announced,
including a $20 million Global Challenge to advance diagnosis and prognosis of
mild TBI.